PubRank

Dominique Mazier

Author PubWeight™ 89.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 2011 3.07
2 A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 2003 2.84
3 Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat Med 2002 2.46
4 Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesis. J Immunol 2003 2.22
5 Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS One 2011 1.60
6 Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. J Immunol 2008 1.53
7 The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood 2010 1.52
8 Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. Cell Host Microbe 2008 1.50
9 A plant-derived morphinan as a novel lead compound active against malaria liver stages. PLoS Med 2006 1.49
10 Plasmodium falciparum--infected erythrocyte adhesion induces caspase activation and apoptosis in human endothelial cells. J Infect Dis 2003 1.44
11 Rapid species diagnosis for invasive candidiasis using mass spectrometry. PLoS One 2010 1.44
12 Sterile protection against malaria is independent of immune responses to the circumsporozoite protein. PLoS One 2007 1.41
13 Helminth infections are associated with protection from cerebral malaria and increased nitrogen derivatives concentrations in Thailand. Am J Trop Med Hyg 2002 1.31
14 MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fluconazole. Proteomics 2009 1.26
15 Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS One 2008 1.25
16 Expression of human CD81 differently affects host cell susceptibility to malaria sporozoites depending on the Plasmodium species. Cell Microbiol 2006 1.25
17 Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. Int J Parasitol 2007 1.24
18 Cholesterol contributes to the organization of tetraspanin-enriched microdomains and to CD81-dependent infection by malaria sporozoites. J Cell Sci 2006 1.23
19 Scavenger receptor BI boosts hepatocyte permissiveness to Plasmodium infection. Cell Host Microbe 2008 1.20
20 Temperature shift and host cell contact up-regulate sporozoite expression of Plasmodium falciparum genes involved in hepatocyte infection. PLoS Pathog 2008 1.19
21 Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening. J Antimicrob Chemother 2006 1.18
22 Selection of a trioxaquine as an antimalarial drug candidate. Proc Natl Acad Sci U S A 2008 1.18
23 In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp. Antimicrob Agents Chemother 2003 1.16
24 Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice. J Immunol 2007 1.14
25 Inhibitory effect of TNF-α on malaria pre-erythrocytic stage development: influence of host hepatocyte/parasite combinations. PLoS One 2011 1.12
26 Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 2012 1.11
27 Decreased hemoglobin concentrations, hyperparasitemia, and severe malaria are associated with increased Plasmodium falciparum gametocyte carriage. J Parasitol 2002 1.10
28 Blood-brain barrier breakdown during cerebral malaria: suicide or murder? Thromb Haemost 2005 1.09
29 New approach for high-throughput screening of drug activity on Plasmodium liver stages. Antimicrob Agents Chemother 2006 1.08
30 Rho kinase inhibition in severe malaria: thwarting parasite-induced collateral damage to endothelia. J Infect Dis 2008 1.06
31 Alternative invasion pathways for Plasmodium berghei sporozoites. Int J Parasitol 2006 1.06
32 The N'-terminal domain of glyceraldehyde-3-phosphate dehydrogenase of the apicomplexan Plasmodium falciparum mediates GTPase Rab2-dependent recruitment to membranes. Biol Chem 2003 1.05
33 Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain. PLoS Pathog 2008 1.05
34 Transfusion-transmitted malaria. Intensive Care Med 2004 1.04
35 Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development. FASEB J 2014 1.04
36 Pseudallescheria/Scedosporium complex species identification by Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry. Med Mycol 2011 1.02
37 Whole-transcriptome analysis of Plasmodium falciparum field isolates: identification of new pathogenicity factors. J Infect Dis 2007 1.01
38 New active drugs against liver stages of Plasmodium predicted by molecular topology. Antimicrob Agents Chemother 2008 1.01
39 A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PLoS One 2009 1.01
40 The Plasmodium sporozoite survives RTS,S vaccination. Trends Parasitol 2005 0.98
41 Transient supplementation of superoxide dismutase protects endothelial cells against Plasmodium falciparum-induced oxidative stress. Mol Biochem Parasitol 2006 0.97
42 Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle. Parasitol Res 2004 0.97
43 Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage. Malar J 2011 0.96
44 Induction of the CD23/nitric oxide pathway in endothelial cells downregulates ICAM-1 expression and decreases cytoadherence of Plasmodium falciparum-infected erythrocytes. Cell Microbiol 2004 0.94
45 Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem Biol 2007 0.94
46 Hepatitis C virus infection may lead to slower emergence of P. falciparum in blood. PLoS One 2011 0.93
47 Intermittent preventive antimalarial treatment to children (IPTc): firebreak or fire trap? Trends Parasitol 2008 0.93
48 Antioxidant and anti-inflammatory properties of a Cucumis melo LC. extract rich in superoxide dismutase activity. J Ethnopharmacol 2004 0.93
49 Differential aiolos expression in human hematopoietic subpopulations. Leuk Res 2009 0.92
50 Metabolic acidosis induced by Plasmodium falciparum intraerythrocytic stages alters blood-brain barrier integrity. J Cereb Blood Flow Metab 2010 0.91
51 Plasmodium falciparum-infected mice: more than a tour de force. Trends Parasitol 2007 0.91
52 Potential value of Plasmodium falciparum-associated antigen and antibody detection for screening of blood donors to prevent transfusion-transmitted malaria. Transfusion 2002 0.91
53 Malaria sporozoite: migrating for a living. Trends Mol Med 2004 0.90
54 IgE mediates killing of intracellular Toxoplasma gondii by human macrophages through CD23-dependent, interleukin-10 sensitive pathway. PLoS One 2011 0.90
55 Aspergillus flavus brain abscesses associated with hepatic amebiasis in a non-neutropenic man in Senegal. Am J Trop Med Hyg 2009 0.89
56 A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS One 2007 0.89
57 Testing blood donors for Chagas disease in the Paris area, France: first results after 18 months of screening. Transfusion 2009 0.89
58 Multilocus phylogeny and MALDI-TOF analysis of the plant pathogenic species Alternaria dauci and relatives. Fungal Biol 2012 0.87
59 Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stage Plasmodium berghei ANKA. Eur J Immunol 2013 0.87
60 Inhibition of Plasmodium falciparum field isolates-mediated endothelial cell apoptosis by Fasudil: therapeutic implications for severe malaria. PLoS One 2010 0.86
61 Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011-2013. Emerg Infect Dis 2015 0.86
62 Skin-draining lymph node priming is sufficient to induce sterile immunity against pre-erythrocytic malaria. EMBO Mol Med 2012 0.85
63 Redox-dependent apoptosis in human endothelial cells after adhesion of Plasmodium falciparum-infected erythrocytes. Ann N Y Acad Sci 2003 0.85
64 Isolation and antimalarial activity of new morphinan alkaloids on Plasmodium yoelii liver stage. Bioorg Med Chem 2008 0.85
65 Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. Blood 2010 0.84
66 Transcriptome of 3D7 and its gametocyte-less derivative F12 Plasmodium falciparum clones during erythrocytic development using a gene-specific microarray assigned to gene regulation, cell cycle and transcription factors. Gene 2004 0.84
67 The Ig domain protein CD9P-1 down-regulates CD81 ability to support Plasmodium yoelii infection. J Biol Chem 2009 0.83
68 Submicroscopic Plasmodium falciparum infections before and after sulfadoxine-pyrimethamine and artesunate association treatment in Dienga, Southeastern Gabon. Clin Med Res 2006 0.83
69 Laser capture microdissection of Plasmodium falciparum liver stages for mRNA analysis. Mol Biochem Parasitol 2002 0.82
70 Deletion of T cells bearing the V beta8.1 T-cell receptor following mouse mammary tumor virus 7 integration confers resistance to murine cerebral malaria. Infect Immun 2002 0.82
71 Specific targeting of caspase-9/PP2A interaction as potential new anti-cancer therapy. PLoS One 2013 0.82
72 CD23 mediates antimycobacterial activity of human macrophages. Infect Immun 2009 0.82
73 Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vet Parasitol 2005 0.82
74 Antimalarial activity of crambescidin 800 and synthetic analogues against liver and blood stage of Plasmodium sp. J Antibiot (Tokyo) 2006 0.81
75 An enhancer-like region regulates hrp3 promoter stage-specific gene expression in the human malaria parasite Plasmodium falciparum. Biochim Biophys Acta 2007 0.80
76 Pooling aqueous humor samples: bias in 2D-LC-MS/MS strategy? J Proteome Res 2010 0.80
77 Cytoadherence and genotype of Plasmodium falciparum strains from symptomatic children in Franceville, southeastern Gabon. Clin Med Res 2007 0.78
78 Supplementation with gliadin-combined plant superoxide dismutase extract promotes antioxidant defences and protects against oxidative stress. Phytother Res 2004 0.78
79 Plasmodium falciparum: hrp3 promoter region is associated with stage-specificity and episomal recombination. Exp Parasitol 2007 0.78
80 Laser capture microdissection of hepatic stages of the human parasite Plasmodium falciparum for molecular analysis. Methods Mol Biol 2005 0.77
81 High levels of immunoglobulin E autoantibody to 14-3-3 epsilon protein correlate with protection against severe Plasmodium falciparum malaria. J Infect Dis 2012 0.77
82 A mouse model for Candida glabrata hematogenous disseminated infection starting from the gut: evaluation of strains with different adhesion properties. PLoS One 2013 0.76
83 Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria. Nat Commun 2017 0.75
84 1,3,5-Triazepane-2,6-diones as structurally diverse and conformationally constrained dipeptide mimetics: identification of malaria liver stage inhibitors from a small pilot library. Chemistry 2006 0.75
85 [CD81: a tetraspanin implicated in Plasmodium infection]. Med Sci (Paris) 2003 0.75
86 Drug hypersensitivity syndrome induced by meglumine antimoniate. Am J Trop Med Hyg 2009 0.75
87 [Cerebral malaria, a key role for endothelial cells?]. J Soc Biol 2004 0.75
88 Wheat gliadin promotes the interleukin-4-induced IgE production by normal human peripheral mononuclear cells through a redox-dependent mechanism. Cytokine 2003 0.75